CABA vs CGEM

Cabaletta Bio, Inc. vs Cullinan Therapeutics, Inc. — Valuation Comparison 2026

CABA

Biological Products, (No Diagnostic Substances)
Cabaletta Bio, Inc.
Quality
4.4
out of 10
Value Trap
24
SAFE
Price
$3.78
Last close
Models
7/13
Active
VS

CGEM

Biological Products, (No Diagnostic Substances)
Cullinan Therapeutics, Inc.
Quality
4.4
out of 10
Value Trap
24
SAFE
Price
$16.44
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType CABA Fair ValueCABA Upside CGEM Fair ValueCGEM Upside
Bayesian DCF Intrinsic $1.06 -72.1% $4.42 -73.1%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.89 -76.5% $1.71 -89.6%
Dynamic NAV Asset-Based $1.45 -61.5% $6.17 -62.4%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for CABA vs CGEM — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CABA vs CGEM — Which Stock Is More Undervalued?

CABA scores higher with a 4.4/10 quality rating vs CGEM's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Cabaletta Bio, Inc. (CABA) and Cullinan Therapeutics, Inc. (CGEM) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CABA currently trades at $3.78 with a QOC of 4.4/10, while CGEM trades at $16.44 with a QOC of 4.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).